3billion Signs MOU with Seoul National University Hospital's Rare Disease Center

On the 23rd, 3billion (CEO Chang-won Geum), an artificial intelligence (AI)-based rare disease diagnosis company, and Seoul National University Hospital Rare Disease Center (Director Jong-hee Chae) announced that they signed a memorandum of understanding (MOU) on the 22nd for the development of genetic diagnosis and treatment for rare diseases.

This agreement aims to jointly promote early diagnosis and development of customized treatments for patients with rare genetic diseases, and its main contents include development and clinical validation of genetic testing technology, research and development of new drugs and treatments, and expansion of clinical research and academic exchanges.

The combination of 3billion's cutting-edge genome analysis technology and Seoul National University Hospital's Rare Disease Center's clinical experience and patient care capabilities is expected to strengthen competitiveness in the field of rare disease diagnosis and treatment.

Seoul National University Hospital's Rare Disease Center is a leading medical institution that conducts various research ranging from molecular diagnosis, genetic and genomic testing to clinical validation of new drug development. The institution's integrated clinical and genomic capabilities, combined with 3billion's genetic mutation interpretation platform, are expected to support more accurate diagnosis and the development of customized treatments.

The signing ceremony was attended by CEO Chang-Won Geum of 3billion, key clinical research directors, Seoul National University Hospital Rare Disease Center Director Jong-Hee Chae, and other officials, and the two sides plan to expand the scope of cooperation through future joint research projects.

Director Chae Jong-hee said, “We expect to achieve world-class precision medicine results in the field of rare diseases by combining the data and diagnostic capabilities of both institutions,” and added, “We hope that this agreement will lead to practical contributions to patient diagnosis, treatment, and prevention.”

CEO Geum Chang-won stated, “We expect to generate tangible results by combining clinical practice and research capabilities, and we will present a new model for precision medicine research on rare diseases both domestically and internationally.”

• See more related articles